Cardinal Health, Inc. · NYSE (us_market)
Healthcare · Medical Distribution · United States
Cardinal Health, Inc. operates as a healthcare services and products company in the United States and internationally. It operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. It distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The company also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; pharmacy management services to hospitals; operates pharmacies, including pharmacies in community health centers; and repackages generic pharmaceuticals and over-the-counter healthcare products. In addition, it manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compression, incontinence, nutritional delivery, and wound care products; single-use surgical drapes, gowns, and apparel products; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. Further, the company distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile and non-sterile procedure kits. Additionally, it manufactures, prepares, and delivers radiopharmaceuticals; and optimizes direct shipments through integrated technology solutions. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2024-03-12$115.62 RISE2024-07-15$93.74 PEAK2024-09-03$114.66 175d | -18.9% 125d | Missed | Missed | — | — | +22.3% 50d | Missed |
DROP2024-03-12$115.62 RISE2024-05-28$94.75 PEAK2024-08-22$110.43 163d | -18.1% 77d | Missed | Missed | — | — | +16.5% 86d | Missed |
DROP2022-04-20$63.86 RISE2022-06-16$50.48 PEAK2022-09-01$71.32 134d | -21.0% 57d | Missed | Missed | — | — | +41.3% 77d | Missed |
DROP2021-07-29$59.99 RISE2021-12-01$45.87 PEAK2022-02-16$54.54 202d | -23.5% 125d | Missed | Missed | — | — | +18.9% 77d | Missed |
DROP2020-08-03$58.04 RISE2020-10-29$45.61 PEAK2020-11-16$58.47 105d | -21.4% 87d | Missed | Missed | — | — | +28.2% 18d | Missed |
DROP2020-06-08$59.31 RISE2020-09-23$45.25 PEAK2020-11-16$58.47 161d | -23.7% 107d | Missed | Missed | — | — | +29.2% 54d | Missed |
DROP2020-06-08$59.31 RISE2020-07-09$48.88 PEAK2020-08-03$58.04 56d | -17.6% 31d | Missed | Missed | — | — | +18.7% 25d | Missed |
DROP2020-02-20$60.42 RISE2020-03-23$41.00 PEAK2020-06-08$59.31 109d | -32.1% 32d | Missed | Missed | — | — | +44.7% 77d | Missed |
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The average brokerage recommendation (ABR) for Cardinal (CAH) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Recent performance snapshot for Cardinal Health (CAH) Cardinal Health (CAH) has moved largely sideways in the short term, with the stock close to flat over the past day and week, and a small gain over the past month. Over the past 3 months, the share price is down about 11%, while the year to date return shows a decline of roughly 2%. Looking further back, the 1 year total return is about 31%, with multi year total returns that are much higher. These mixed returns come alongside reported...
CAH's fast-growing Other Growth Businesses posted 34% revenue growth and 52% profit gains, raising their role in long-term earnings.
CAH's fast-growing Other Growth Businesses posted 34% revenue growth and 52% profit gains, raising their role in long-term earnings.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Cardinal Health (NYSE:CAH) and the best and worst performers in the healthcare providers & services industry.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Cardinal Health (NYSE:CAH) and the best and worst performers in the healthcare providers & services industry.
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Cardinal Health's specialty growth, strong cash flow and expanding higher-margin businesses are boosting earnings momentum despite IRA and GMPD risks.
Cardinal Health's specialty growth, strong cash flow and expanding higher-margin businesses are boosting earnings momentum despite IRA and GMPD risks.
Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.
Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.
Over the past year, many Cardinal Health, Inc. ( NYSE:CAH ) insiders sold a significant stake in the company which may...
Over the past year, many Cardinal Health, Inc. ( NYSE:CAH ) insiders sold a significant stake in the company which may...
Cardinal Health is expanding beyond drug distribution into specialty care, logistics and nuclear medicine, deepening its role in US healthcare infrastructure.
Cardinal Health is expanding beyond drug distribution into specialty care, logistics and nuclear medicine, deepening its role in US healthcare infrastructure.
ANGO gains momentum as NanoKnife adoption, strong Med Tech growth and positive clinical trends support its long-term outlook.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| CAH | +0.80% | -14.39% | -4.23% | +27.43% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -2.17% | -8.68% | -0.79% | +14.74% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 12.07M | $2.55B | 0.09% | Trimmed-3.5% | 2026-03-31 |
| Wellington | fundamental | 4.28M | $903.59M | 0.17% | Trimmed-17.2% | 2026-03-31 |
| FidelityFMR | fundamental | 4.24M | $896.64M | 0.05% | Trimmed-7.8% | 2026-03-31 |
| TwoSigma | quant | 439.9K | $92.95M | 0.08% | Trimmed-45.4% | 2026-03-31 |
| Citadel | multi-strat | 420.4K | $88.84M | 0.11% | Trimmed-23.3% | 2026-03-31 |
| DEShaw | quant | 365.2K | $77.16M | 0.05% | Trimmed-25.4% | 2026-03-31 |
| RenTech | quant | 344.8K | $72.86M | 0.11% | Trimmed-55.4% | 2026-03-31 |
| Bridgewater | macro | 115.2K | $24.35M | 0.11% | Trimmed-46.8% | 2026-03-31 |
| TRowePrice | fundamental | 1.87M | $395.51K | 0.05% | Unchanged | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-04-17 | Hall Patricia Hemingway | Director | A Grant / award | 381 | $207.83 | +$79.2K |
| 2026-03-03 | Greene Michelle D. | Chief Information Officer | S Open-market sale | 2,646 | $228.47 | −$604.5K |
| 2026-03-03 | Greene Michelle D. | Chief Information Officer | S Open-market sale | 100 | $228.55 | −$22.9K |
| 2026-02-18 | Alt Aaron E | Chief Financial Officer | S Open-market sale | 2,328 | $225.50 | −$525.0K |
| 2026-02-18 | Alt Aaron E | Chief Financial Officer | F Tax withholding | 1,914 | $220.79 | −$422.6K |
| 2026-02-10 | Hall Patricia Hemingway | Director | S Open-market sale | 4,000 | $229.72 | −$918.9K |
| 2026-01-20 | Pitteroff Valerie Christine | Chief Human Resources Officer | A Grant / award | 3,982 | $213.26 | +$849.2K |
| 2025-12-02 | Snow Ola M | Chief Human Resources Officer | F Tax withholding | 320 | $212.26 | −$67.9K |
| 2025-12-02 | Mason Stephen M | CEO, GMPD Segment | F Tax withholding | 595 | $212.26 | −$126.3K |
| 2025-12-02 | Scherer Mary C. | Chief Accounting Officer | F Tax withholding | 61 | $212.26 | −$12.9K |
| 2025-12-02 | WEITZMAN DEBORAH | CEO, PSS Segment | F Tax withholding | 551 | $212.26 | −$117.0K |
| 2025-12-02 | Mayer Jessica L | Chief Legal/Compliance Officer | F Tax withholding | 422 | $212.26 | −$89.6K |
| 2025-11-06 | Azelby Robert | Director | A Grant / award | 1,067 | — | +$0 |
| 2025-11-06 | Brennan Michelle | Director | A Grant / award | 1,067 | — | +$0 |
| 2025-11-06 | Edison Sheri H. | Director | A Grant / award | 1,067 | — | +$0 |
| 2025-11-06 | Evans David C | Director | A Grant / award | 1,067 | — | +$0 |
| 2025-11-06 | Hall Patricia Hemingway | Director | A Grant / award | 1,067 | — | +$0 |
| 2025-11-06 | JOHRI AKHIL | Director | A Grant / award | 1,067 | — | +$0 |
| 2025-11-06 | KENNY GREGORY B | Director | A Grant / award | 1,702 | — | +$0 |
| 2025-11-06 | Killefer Nancy | Director | A Grant / award | 1,067 | — | +$0 |
| 2025-11-06 | MUNDKUR CHRISTINE | Director | A Grant / award | 1,067 | — | +$0 |
| 2025-11-06 | Musslewhite Robert W | Director | A Grant / award | 1,067 | — | +$0 |
| 2025-11-06 | Ramakrishna Sudhakar | Director | A Grant / award | 1,067 | — | +$0 |
| 2025-08-20 | Hollar Jason M. | Chief Executive Officer | S Open-market sale | 22,957 | $150.40 | −$3.45M |
| 2025-08-20 | Hollar Jason M. | Chief Executive Officer | S Open-market sale | 12,944 | $149.40 | −$1.93M |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-18upcoming | 2.41 | — | — |
| 2026-04-30 | 2.79 | 3.17 | +13.70% |
| 2026-02-05 | 2.37 | 2.63 | +11.17% |
| 2025-10-30 | 2.17 | 2.55 | +17.60% |
| 2025-08-12 | 2.03 | 2.08 | +2.36% |
| 2025-05-01 | 2.15 | 2.35 | +9.36% |
| 2025-01-30 | 1.76 | 1.93 | +9.39% |
| 2024-11-01 | 1.62 | 1.88 | +15.88% |
| 2024-08-14 | 1.73 | 1.84 | +6.27% |
| 2024-05-02 | 1.95 | 2.08 | +6.63% |
| 2024-02-01 | 1.60 | 1.82 | +14.00% |
| 2023-11-03 | 1.41 | 1.73 | +22.98% |
| 2023-08-15 | 1.48 | 1.55 | +4.86% |
| 2023-05-04 | 1.49 | 1.74 | +16.77% |
| 2023-02-02 | 1.14 | 1.32 | +15.33% |
| 2022-11-04 | 0.97 | 1.20 | +24.12% |